New hope for patients with transformed lung cancer
NCT ID NCT06830694
Summary
This study is testing whether adding a new drug called tarlatamab to standard chemotherapy and immunotherapy can better control a rare and aggressive form of lung cancer. It is for patients whose initial lung cancer transformed into a different, faster-growing type after previous treatment. The main goal is to see if this combination can keep the cancer from progressing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.